MedTrace Logo

A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

NCT04108247 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2022-07-07

No results posted yet for this study

Summary

The aim of this trial is to evaluate the Drug-Drug interaction with Abiraterone combined with SHR3162 in the Metastatic Castration Resistant Prostate Cancer Patients.

Conditions

  • Prostate Cancer Castration-resistant Prostate Cancer

Interventions

DRUG

Abiraterone+SHR3162

Participants will receive Abiraterone combined with SHR3162 orally

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04108247 on ClinicalTrials.gov